PressRelease
Cleanascite™Cited in Nanopore Detection of Anticancer Drug
MONMOUTHJUNCTION, NJ, November 24, 2025 — Biotech Support Group (BSG)reports on its proprietary lipid removal reagent, Cleanascite™,in a nanopore detection study of the anticancer drug, Actinomycin D.
Researchersfrom the University of Missouri, published an article entitled “ALabel-free Nanopore Biosensor for Rapid and Highly SensitiveDetection of Actinomycin in Human Serum”,utilizing Cleanascite™as sample prep to remove deleterious matrix effects from human serum.
ActinomycinD (ActD), a potent anticancer drug, binds specifically to DNA atGpC-rich sites. Detecting trace levels of ActD in human serum, iscrucial for clinical, environmental, and pharmaceutical applications.For this purpose,a label-free detection method using an engineered αhemolysin (α-HL) nanopore was developed. Yet, human serum containscomponents, such as lipoproteins, that can disrupt the fragile lipidbilayer used to support the nanopore and/or cause frequent andlong-duration channel blockage. Therefore, direct analysis of humanserum by biological nanopore is challenging.
Toovercome this matrix effect, the samples were first treated withCleanascite™. Upon treatment, the results demonstrate that thematrix components in serum do not significantly interfere with ActDdetection holding promise for clinical applications. Finally, thisDNA-based nanopore platform offers a powerful, label-free tool fordrug screening and discovery.
“Cleanascite™is now commonly used in many serum applications to remove matrixeffects and maintain the integrity of finely tuned instruments. Thisis one of many references that demonstrate its advantaged workflow asa simple yet cost-effective sample prep product to clear lipidfactors from serum or plasma, without interfering with downstreamanalysis.” stated Dr. Swapan Roy, President and Founder of BiotechSupport Group.
Foradditional product details, visit:
Cleanascite™Lipid Removal Reagent
AboutBiotech Support Group LLC
BiotechSupport Group develops innovative sample preparation technologiesthat address the emerging needs of proteomics, biomarker discovery,and personalized medicine. Flagship products include Cleanascite™for lipid removal, AlbuVoid™ and AlbuSorb™ PLUS for serum proteindepletion, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NRicher™ for low abundance, family specific, and targetedproteome enrichment.These products support translational research by simplifyingworkflows and improving sample quality for downstream analysis.
ForBusiness Development Inquiries:
Matthew Kuruc
Phone:732-274-2866
Email: [email protected]
Keywords:Cleanascite™, serum lipid depletion, biological nanopore,actinomycin D, DNA-drug interaction, label-free drug screening